PMID: 7546151Jan 1, 1995Paper

Hypertension two years after renal transplantation: causes and consequences

Transplant International : Official Journal of the European Society for Organ Transplantation
C WarholmE Pettersson

Abstract

The incidence of hypertension 2 years after renal transplantation and the possible causes of hypertension were studied retrospectively. A group of 93 patients treated with cyclosporin (CyA), azathioprine (Aza), and/or prednisolone (Pred) were compared to a group of 31 patients treated with Aza and Pred. There were more patients with hypertension in the CyA group (73%) than in the Aza group (58%). Hypertension before transplantation predisposed to hypertension after transplantation. After transplantation, hypertension was most common among patients with polycystic kidney disease (46%), chronic glomerulonephritis (67%), and diabetes (71%). The accumulated immunosuppressive medication (CyA/Pred) did not affect the occurrence of hypertension. Hypertensive patients had significantly poorer graft function than did normotensive patients (serum creatinine level 229 mumol/l vs 162 mumol/l, P < 0.01). The 10-year graft survival was markedly impaired in the group with hypertension (42% vs 65% for normotensives, P < 0.05). The 10-year patient survival was 59% vs 79% (P = NS). The study further confirms the frequent finding that hypertension has a negative effect on graft and patient survival rates.

References

Jun 1, 1992·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·P C BrazyF O Belzer
May 1, 1992·Transplant International : Official Journal of the European Society for Organ Transplantation·H E WilczekS O Bohman
Dec 1, 1991·Annals of Surgery·E J SchweitzerJ S Najarian
Aug 1, 1991·Transplantation·F M ModenaM E Rosenberg
Apr 1, 1990·Journal of Internal Medicine·A Kuskowska-Wolk, S Rössner
May 1, 1990·Kidney International·W E Braun
Jan 1, 1989·Clinical and Experimental Hypertension. Part A, Theory and Practice
Feb 1, 1989·Transplantation·S Y ShenT R Coughlin
Feb 1, 1989·Kidney International·P C BrazyJ F Fitzwilliam
Feb 1, 1994·Kidney International·M E RosenbergT H Hostetter

❮ Previous
Next ❯

Citations

Jan 10, 2006·Seminars in Dialysis·Elizabeth A Kendrick, Connie L Davis
Oct 24, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Tomás Seeman
Apr 11, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·G V Ramesh PrasadJeffrey S Zaltzman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.